Testing for Mold Toxicity
There is currently no validated method to test humans for toxigenic mold exposure, and routine laboratory testing for mold toxicity is not recommended. 1
The Evidence-Based Approach
The American Academy of Pediatrics guidelines explicitly state that there are no uniformly accepted, valid serologic tests or quantitative environmental sampling methods to assess mold exposure 1. More importantly, there is currently no method to test humans for toxigenic mold exposure 1. This represents the strongest guideline-level evidence available and should guide clinical practice.
What Testing IS Appropriate
For Allergic Disease (IgE-Mediated)
If you suspect mold-related allergic disease, the workup should include:
- Skin prick testing for mold allergens
- Specific IgE antibody measurements for mold species
- Provocation testing when indicated
- Cellular test systems as supplementary evaluation 2
This approach is only appropriate when there is evidence of atopy on history and physical examination 2, 3.
For Immunocompromised Patients
If the patient has significant immunosuppression (grade 2-3 per KRINKO/RKI classification), the priority is immediate cessation of mold exposure, not testing 2, 4. If invasive fungal infection is suspected:
- Radiological imaging
- Microbiological cultures
- Serological testing (e.g., galactomannan, beta-D-glucan)
- Immunological evaluation 2
What Testing to AVOID
Not Recommended for Clinical Diagnosis:
- Blood or urine tests for mold components or metabolites 2, 4
- Indoor measurements of mold fungi for medical evaluation 2, 4, 3
- Microbial volatile organic compound (MVOC) testing 2
- Mycotoxin testing in blood, urine, or environmental samples 2, 3
- Immunoassays for mold (not standardized for clinical use) 1
The updated 2023 AWMF guideline reinforces that indoor measurements are generally not indicated as part of medical evaluation 2, 4.
Clinical Reasoning
The concept of "toxic mold syndrome" remains controversial and lacks scientific validation 5, 6. While molds cause well-established diseases through three mechanisms—allergy, infection, and oral toxicosis—the evidence for inhalational mycotoxin toxicity causing systemic illness is insufficient 6.
Common Pitfalls:
- Ordering unvalidated mycotoxin panels: These tests lack standardization and clinical correlation 3
- Environmental testing for diagnosis: Visible mold or musty odor is sufficient evidence; quantitative testing doesn't predict health effects 1
- Attributing non-specific symptoms to "mold toxicity": Many patients have alternative diagnoses that explain their symptoms 6
The Practical Algorithm
- Take a targeted history: Document respiratory symptoms, immune status, atopic history, and evidence of water damage/visible mold in the home
- Physical examination: Look for pale nasal mucosa, pharyngeal cobblestoning, rhinorrhea 5
- If atopic features present: Proceed with allergy testing (skin prick or specific IgE)
- If immunocompromised: Focus on exposure elimination and infection workup if clinically indicated
- If non-specific symptoms: Look for alternative diagnoses rather than attributing to "mold toxicity"
Special Consideration for Dietary Mycotoxins
The only exception is suspected mycotoxin-contaminated food ingestion (especially grains), where dietary history is appropriate 1. However, this is regulated by the USDA and rarely causes clinical illness.
Bottom Line
Focus clinical efforts on identifying allergic disease or infection rather than pursuing unvalidated "toxicity" testing. The priority should be source elimination (remediating water damage within 24 hours) rather than quantifying exposure 1. For patients at risk (immunosuppressed, severe asthma, cystic fibrosis), immediate exposure cessation takes precedence over any diagnostic testing 4, 3.